deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT01458366

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas

Sponsor: GlaxoSmithKline

Conditions Non-Hodgkin's Lymphoma
Interventions Bendamustine CT Scan Carboplatin Etoposide Ofatumumab PET Scan Stem Cell Transplant (STC)
Updated 15 times since 2017 Last updated: Apr 28, 2025 Started: Nov 9, 2011 Primary completion: Aug 27, 2018 Completion: Jul 23, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Non-Hodgkin's Lymphoma and is currently completed. GlaxoSmithKline leads this study, which shows 15 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Jan 2024 · 16 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. May 2025 — Feb 2026 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Sep 2022 — Jan 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jun 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jul 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Novartis
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations